GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02490176

UnknownPhase NA

Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure

Lead sponsor

Chinese PLA General Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Heart failure

Key I/E criterion

•EF ≤50%

Primary endpoint

•A change in cardiac output

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02490176

Org study IDS2015-095-01

Timeline

Milestones

Study first posted2015-07-03estimated

Last update posted2016-02-29estimated

Study start2015-07 (month precision)

Primary completion2016-07estimated (month precision)

Study completion2016-07estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Heart failure

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

Patients with HF were eligible for the study. Diagnosis of HF was based on an impaired ejection fraction (<50%).

Exclusion criteria

Patients were also excluded for the following reasons: unconscious at presentation; valvular heart disease, cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; or renal insufficiency.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Heart failure

Other (unclassified)

Heart failure

1 endpoint

Primary/protocol endpoint

a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology

Time frame:7 days after treatment

change from baseline, improvement

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

a change in left ventricular contractile index measured by PiCCO technology

Time frame:7 days after treatment

change from baseline, descriptive

Publications (7)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
European heart journal2012 Jun (month)PMID21920963doi:10.1093/eurheartj/ehr309via CT.gov background
Hemodynamic monitoring by transpulmonary thermodilution and pulse contour analysis in critically ill children.
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies2011 Jul (month)PMID21263372doi:10.1097/PCC.0b013e3182070959via CT.gov background
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Diabetes2009 Apr (month)PMID19151200doi:10.2337/db08-1193via CT.gov background
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Journal of the American College of Cardiology2009 Feb 10PMID19195607doi:10.1016/j.jacc.2008.10.033via CT.gov background
Effects of Bulbus allii macrostemi on clinical outcomes and oxidized low-density lipoprotein and plasminogen in unstable angina/non-ST-segment elevation myocardial infarction patients.
Phytotherapy research : PTR2008 Nov (month)PMID18688814doi:10.1002/ptr.2534via CT.gov background
Intensive pharmacologic treatment in patients with acute non ST-segment elevation myocardial infarction who did not undergo percutaneous coronary intervention.
Circulation journal : official journal of the Japanese Circulation Society2008 Sep (month)PMID18724013doi:10.1253/circj.cj-08-0048via CT.gov background
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Circulation2004 Mar 2PMID14981009doi:10.1161/01.CIR.0000120505.91348.58via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.